GSK Announces U.S. FDA Approval of Benlysta (Belimumab) For Pediatric Patients With Active Lupus Nephritis
GSK plc (NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving
Medicenna Announces New Clinical Data Providing Preliminary Evidence Of MDNA11’s Single Agent Anti-Cancer Activity In The Phase 1/2 ABILITY Study
-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study’s low and mid-stage dose escalation cohorts
--
Mustang Bio Announces First Patient Successfully Treated By Ex Vivo Lentiviral Gene Therapy To Treat RAG1 Severe Combined Immunodeficiency
Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for
Soligenix Receives Agreement From FDA On Initial Pediatric Study Plan For HyBryte For The Treatment Of Cutaneous T-Cell Lymphoma
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced
Oramed Reaches 50% Enrollment In Its Second Phase 3 Oral Insulin Trial
- ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol
- ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023
Diffusion Pharmaceuticals To Initiate Phase 2 Trial In Patients With Glioblastoma Multiforme Incorporating Innovative Imaging Methodology To Evaluate Tumor Oxygenation
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)
Bausch + Lomb Enrolls First Patient In LASIK Clinical Trial Evaluating Use Of Technolas TENEO™ Excimer Laser For Vision Correction Surgery for Hyperopia with Astigmatism
Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that the company has enrolled the first patient